SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER

Juan Li,Ruyu Ai,Mingyao Lai,Qingjun Hu,Linbo Cai

DOI: https://doi.org/10.1093/noajnl/vdad070.078

2023-01-01

Neuro-Oncology Advances

Abstract:Abstract BACKGROUND Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and highly aggressive tumor that occurs most commonly in infants and young children. The prognosis for patients with AT/RT is generally poor, with a five-year survival rate of less than 30%. METHODS We retrospectively analyzed the clinical data of patients with AT/RT in the past 10 years at the Guangdong Sanjiu Brain Hospital RESULTS A total of 18 cases (male/female = 9:9; median age at diagnosis, 3.5 years (range 1-58 years old)) were diagnosed with AT/RT between 2017 and 2023. AT/RT had higher prevalence in children < 36 months (55.6%), and at infratentorial (66.7%). The median follow-up time was 15.5 months, with a range of 2-62 months. Survival analyses demonstrated that patients > 3 years of age (n = 9 (50%)) had median survival time 28months and patients ≤ 3 years of age (n = 9 (50%)) had median- survival time 15 months (p =0.034) The average survival time for disseminated tumor was 15 months, and for patients with localizedtumors was 44 months. (P=0.012) CONCLUSION Older age, localized tumor improves the survival of patients with AT/RT.